Latifa Koussih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Latifa Koussih has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abdelhabib Semlali
GREB Research Group, Faculty of Dentistry, Laval University, Québec, QC G1V 0A6, Canada
3 shared publications - Hawraa Issa
DREAM-CV Lab, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
3 shared publications - Mahmoud Rouabhia
Groupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire, Université Laval, 2420 rue de la Terrasse, Québec, QC G1V 0A6, Canada
3 shared publications - Manal Dahdah
GREB Research Group, Faculty of Dentistry, Laval University, Québec, QC G1V 0A6, Canada
3 shared publications - Mikhlid H. Almutairi
Zoology Department, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
3 shared publications - Yasmine Ettouil
GREB Research Group, Faculty of Dentistry, Laval University, Québec, QC G1V 0A6, Canada
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8825
Viroelixir Exhibits Cell-Line-Specific Anticancer Activity and Enhances Chemosensitivity in Oral Squamous Cell Carcinoma: Associated Changes in Apoptosis, Redox Homeostasis, and Oncogenic Signaling
Oral squamous cell carcinoma (OSCC) remains a major global health burden despite advances in surgery, radiotherapy, and chemotherapy. The development of novel therapeutic agents with improved efficacy and reduced toxicity is therefore urgently needed. This study investigated the anticancer potential of Viroelixir, a natural formulation derived from green tea and pomegranate extracts and explored its underlying molecular mechanisms in oral cancer cells. Human gingival squamous cell carcinoma cells (Ca9-22), tongue squamous cell carcinoma cells (CAL-27 and SCC-9), and non-tumorigenic oral epithelial cells (GMSM-K) were exposed to serial dilutions of Viroelixir. Cell viability, membrane damage, clonogenic survival, apoptosis, autophagy, redox status, migration, protein expression, and responses to cisplatin or 5-fluorouracil (5-FU) were assessed using MTT and LDH assays, crystal-violet staining, flow cytometry, and wound-healing assays. Viroelixir preferentially reduced Ca9-22 viability and clonogenic survival while having limited effects on GMSM-K, CAL-27, and SCC-9SCC-9 viability over 24 h of Viroelixir exposure. In Ca9-22 cells, Viroelixir increased p21, p27, and p53 and reduced Cyclin D1, a profile consistent with inhibition of G1/S progression. It promoted mitochondrial apoptosis, reduced autophagy-associated signals and LC3B expression, increased intracellular ROS and mitochondrial superoxide, depleted glutathione, and reduced wound closure while increasing E-cadherin and reducing fibronectin. Viroelixir also reduced phosphorylation of p38, ERK1/2, STAT3, NF-kappaB, and AKT1. In addition, Viroelixir enhanced the antiproliferative effects of cisplatin and 5-fluorouracil. Viroelixir exhibits a pronounced cell-line-specific anticancer response, with Ca9-22 gingival carcinoma cells displaying substantially greater sensitivity than the other oral cell models tested. This response is associated with coordinated changes in cell-cycle regulatory proteins, mitochondrial apoptosis, autophagy-associated signals, redox homeostasis, and oncogenic signaling. Viroelixir also enhances the antiproliferative effects of cisplatin and 5-FU, supporting further investigation of this formulation in OSCC. These findings support its potential development as a novel adjuvant therapeutic agent for gingival squamous cell carcinoma management.
- 2 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8825
Open AccessViroelixir Exhibits Cell-Line-Specific Anticancer Activity and Enhances Chemosensitivity in Oral Squamous Cell Carcinoma: Associated Changes in Apoptosis, Redox Homeostasis, and Oncogenic Signaling
Oral squamous cell carcinoma (OSCC) remains a major global health burden despite advances in surgery, radiotherapy, and chemotherapy. The development of novel therapeutic agents with improved efficacy and reduced toxicity is therefore urgently needed. This study investigated the anticancer potential of Viroelixir, a natural formulation derived from green tea and pomegranate extracts and explored its underlying molecular mechanisms in oral cancer cells. Human gingival squamous cell carcinoma cells (Ca9-22), tongue squamous cell carcinoma cells (CAL-27 and SCC-9), and non-tumorigenic oral epithelial cells (GMSM-K) were exposed to serial dilutions of Viroelixir. Cell viability, membrane damage, clonogenic survival, apoptosis, autophagy, redox status, migration, protein expression, and responses to cisplatin or 5-fluorouracil (5-FU) were assessed using MTT and LDH assays, crystal-violet staining, flow cytometry, and wound-healing assays. Viroelixir preferentially reduced Ca9-22 viability and clonogenic survival while having limited effects on GMSM-K, CAL-27, and SCC-9SCC-9 viability over 24 h of Viroelixir exposure. In Ca9-22 cells, Viroelixir increased p21, p27, and p53 and reduced Cyclin D1, a profile consistent with inhibition of G1/S progression. It promoted mitochondrial apoptosis, reduced autophagy-associated signals and LC3B expression, increased intracellular ROS and mitochondrial superoxide, depleted glutathione, and reduced wound closure while increasing E-cadherin and reducing fibronectin. Viroelixir also reduced phosphorylation of p38, ERK1/2, STAT3, NF-kappaB, and AKT1. In addition, Viroelixir enhanced the antiproliferative effects of cisplatin and 5-fluorouracil. Viroelixir exhibits a pronounced cell-line-specific anticancer response, with Ca9-22 gingival carcinoma cells displaying substantially greater sensitivity than the other oral cell models tested. This response is associated with coordinated changes in cell-cycle regulatory proteins, mitochondrial apoptosis, autophagy-associated signals, redox homeostasis, and oncogenic signaling. Viroelixir also enhances the antiproliferative effects of cisplatin and 5-FU, supporting further investigation of this formulation in OSCC. These findings support its potential development as a novel adjuvant therapeutic agent for gingival squamous cell carcinoma management.
- Open Access
- 21 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 420
Evaluation of the Antifungal Activity of the Polyphenol Formulation Viroelixir Against Candida albicans
Candida albicans (C. albicans) is an opportunistic fungal pathogen capable of causing a wide range of infections, including mucosal and systemic candidiasis. In the oral cavity, fungi represent a minor component of the microbiome but can significantly contribute to morbidity, particularly under conditions of dysbiosis or immunosuppression. Treatment remains challenging due to increasing multidrug resistance. This study investigates the in vitro antifungal potential of Viroelixir, a standardized polyphenol blend derived from green tea and pomegranate and enriched in catechins (including epigallocatechin gallate, EGCG), ellagitannins (notably punicalagin), ellagic acid, and flavonoids, with particular focus on its potential anti-virulence mechanisms. Methods: The effect of Viroelixir on C. albicans growth was assessed using MTT assay, optical density measurements, colony formation, carbohydrate quantification, and pH variation analysis. Biofilm formation, morphological transition, ROS production, necrosis, virulence gene expression, adhesion, and host immune responses were also evaluated. Results: Viroelixir significantly inhibited C. albicans growth and reduced colony formation compared with untreated controls. The formulation also inhibited biofilm formation and markedly reduced pseudohyphal development, reaching up to 94% reduction under specific treatment conditions. Flow cytometry analysis showed an increase in dead fungal cells, reaching approximately 88% following exposure to Viroelixir at the highest tested concentration. In addition, Viroelixir reduced the transcript levels of several virulence-associated genes, including SAP1–SAP9 and EAP1. In epithelial cell co-culture models, pre-treatment of C. albicans with Viroelixir reduced fungal adhesion and attenuated epithelial inflammatory responses, including IL-6, IL-8, and hBD-2 production, and was associated with reduced activation of the TLR4-NF-κB signaling pathway. Conclusions: These findings suggest that the antifungal and anti-virulence effects observed may be associated with the polyphenolic compounds present in the Viroelixir formulation, highlighting its potential as a promising in vitro antifungal candidate against C. albicans.
- 21 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 420
Open AccessEvaluation of the Antifungal Activity of the Polyphenol Formulation Viroelixir Against Candida albicans
Candida albicans (C. albicans) is an opportunistic fungal pathogen capable of causing a wide range of infections, including mucosal and systemic candidiasis. In the oral cavity, fungi represent a minor component of the microbiome but can significantly contribute to morbidity, particularly under conditions of dysbiosis or immunosuppression. Treatment remains challenging due to increasing multidrug resistance. This study investigates the in vitro antifungal potential of Viroelixir, a standardized polyphenol blend derived from green tea and pomegranate and enriched in catechins (including epigallocatechin gallate, EGCG), ellagitannins (notably punicalagin), ellagic acid, and flavonoids, with particular focus on its potential anti-virulence mechanisms. Methods: The effect of Viroelixir on C. albicans growth was assessed using MTT assay, optical density measurements, colony formation, carbohydrate quantification, and pH variation analysis. Biofilm formation, morphological transition, ROS production, necrosis, virulence gene expression, adhesion, and host immune responses were also evaluated. Results: Viroelixir significantly inhibited C. albicans growth and reduced colony formation compared with untreated controls. The formulation also inhibited biofilm formation and markedly reduced pseudohyphal development, reaching up to 94% reduction under specific treatment conditions. Flow cytometry analysis showed an increase in dead fungal cells, reaching approximately 88% following exposure to Viroelixir at the highest tested concentration. In addition, Viroelixir reduced the transcript levels of several virulence-associated genes, including SAP1–SAP9 and EAP1. In epithelial cell co-culture models, pre-treatment of C. albicans with Viroelixir reduced fungal adhesion and attenuated epithelial inflammatory responses, including IL-6, IL-8, and hBD-2 production, and was associated with reduced activation of the TLR4-NF-κB signaling pathway. Conclusions: These findings suggest that the antifungal and anti-virulence effects observed may be associated with the polyphenolic compounds present in the Viroelixir formulation, highlighting its potential as a promising in vitro antifungal candidate against C. albicans.
- Open Access
- 17 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 406
Mechanistic Insights into the Anti-Virulence Effects of Viroelixir, a Phenolic Blend from Green Tea and Pomegranate, on Streptococcus mutans
Background: Dental caries remains one of the most prevalent oral diseases worldwide, largely driven by the virulence of Streptococcus mutans. Although plant phenolics from green tea and pomegranate are known for their antimicrobial properties, their molecular mechanisms of action against key S. mutans virulence targets remain insufficiently characterized. Aim: This study investigated the antibacterial and anti-virulence properties of Viroelixir, a phenolic-rich formulation derived from green tea (Camellia sinensis) and pomegranate (Punica granatum), against S. mutans, with particular emphasis on predictive molecular docking interactions with critical virulence-associated proteins. Methods: Viroelixir phytochemical composition was characterized by LC–MS using a C18 reverse-phase column and negative electrospray ionization mode. Antibacterial activity was evaluated using growth kinetics, agar plating, and crystal violet assays. Acidogenicity, hemolytic activity, and biofilm formation were assessed using pH modulation, hemolysis assays, SEM, and biofilm biomass quantification. Virulence gene expression was analyzed by RT-qPCR. In silico molecular docking was performed to explore potential interactions between major LC–MS-supported phenolic constituents and S. mutans virulence proteins, including glucosyltransferase B (GtfB), LuxS, and SpaP. Biocompatibility was evaluated in human gingival epithelial cells. Results: The LC-MS analysis revealed a complex mixture of phenolic compounds consistent with catechins and ellagitannins. Compound identification was considered tentative and based on mass spectral range and chromatographic behavior. Viroelixir significantly inhibited S. mutans growth, acid production, hemolytic activity, and biofilm formation in a concentration-dependent manner. Key virulence genes were markedly downregulated. Docking analyses suggested stable binding of selected phenolics—particularly punicalagin, catechin, and epigallocatechin—within the active sites of GtfB, LuxS, and SpaP. Importantly, Viroelixir showed no cytotoxic effects on gingival epithelial cells. Conclusions: Viroelixir exerts potent antibacterial and anti-virulence effects against S. mutans through a multi-target mechanism combining transcriptional suppression and predictive molecular inhibition of virulence proteins, supporting its potential as a safe, natural therapeutic for caries prevention.
- 17 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 406
Open AccessMechanistic Insights into the Anti-Virulence Effects of Viroelixir, a Phenolic Blend from Green Tea and Pomegranate, on Streptococcus mutans
Background: Dental caries remains one of the most prevalent oral diseases worldwide, largely driven by the virulence of Streptococcus mutans. Although plant phenolics from green tea and pomegranate are known for their antimicrobial properties, their molecular mechanisms of action against key S. mutans virulence targets remain insufficiently characterized. Aim: This study investigated the antibacterial and anti-virulence properties of Viroelixir, a phenolic-rich formulation derived from green tea (Camellia sinensis) and pomegranate (Punica granatum), against S. mutans, with particular emphasis on predictive molecular docking interactions with critical virulence-associated proteins. Methods: Viroelixir phytochemical composition was characterized by LC–MS using a C18 reverse-phase column and negative electrospray ionization mode. Antibacterial activity was evaluated using growth kinetics, agar plating, and crystal violet assays. Acidogenicity, hemolytic activity, and biofilm formation were assessed using pH modulation, hemolysis assays, SEM, and biofilm biomass quantification. Virulence gene expression was analyzed by RT-qPCR. In silico molecular docking was performed to explore potential interactions between major LC–MS-supported phenolic constituents and S. mutans virulence proteins, including glucosyltransferase B (GtfB), LuxS, and SpaP. Biocompatibility was evaluated in human gingival epithelial cells. Results: The LC-MS analysis revealed a complex mixture of phenolic compounds consistent with catechins and ellagitannins. Compound identification was considered tentative and based on mass spectral range and chromatographic behavior. Viroelixir significantly inhibited S. mutans growth, acid production, hemolytic activity, and biofilm formation in a concentration-dependent manner. Key virulence genes were markedly downregulated. Docking analyses suggested stable binding of selected phenolics—particularly punicalagin, catechin, and epigallocatechin—within the active sites of GtfB, LuxS, and SpaP. Importantly, Viroelixir showed no cytotoxic effects on gingival epithelial cells. Conclusions: Viroelixir exerts potent antibacterial and anti-virulence effects against S. mutans through a multi-target mechanism combining transcriptional suppression and predictive molecular inhibition of virulence proteins, supporting its potential as a safe, natural therapeutic for caries prevention.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4, 127
Pentraxin 3: An Immuno-Regulator in the Lungs
Pentraxin 3 (PTX3) is a soluble pattern recognition receptor that is a humoral component of the innate immune system. It interacts with pathogenic moieties, infected and dying host cells and facilitates their removal through activation of appropriate innate and adaptive mechanisms. PTX3 is secreted by a diverse variety of cells, ranging from immune cells to structural cells, in response to Toll like receptor (TLR) engagement, inflammatory stimuli, and physical and chemical stress. Further, PTX3 plays an essential role in female fertility as it facilitates the organization of extracellular matrix in the cumulus oophorus. Such activity is also implicated in post-inflammation tissue repair. PTX3 is a multifunctional protein and plays a non-redundant role in providing immunity against potential immunological dangers. Thus, we assessed its role in lung immunity, as lungs are at a constant risk of infections and tissue damage that is attributable to perpetual exposure to foreign agents.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4, 127
Open AccessPentraxin 3: An Immuno-Regulator in the Lungs
Pentraxin 3 (PTX3) is a soluble pattern recognition receptor that is a humoral component of the innate immune system. It interacts with pathogenic moieties, infected and dying host cells and facilitates their removal through activation of appropriate innate and adaptive mechanisms. PTX3 is secreted by a diverse variety of cells, ranging from immune cells to structural cells, in response to Toll like receptor (TLR) engagement, inflammatory stimuli, and physical and chemical stress. Further, PTX3 plays an essential role in female fertility as it facilitates the organization of extracellular matrix in the cumulus oophorus. Such activity is also implicated in post-inflammation tissue repair. PTX3 is a multifunctional protein and plays a non-redundant role in providing immunity against potential immunological dangers. Thus, we assessed its role in lung immunity, as lungs are at a constant risk of infections and tissue damage that is attributable to perpetual exposure to foreign agents.